Impact on clinical outcomes of right ventricular response to percutaneous correction of secondary mitral regurgitation

Aims In patients with heart failure and reduced ejection fraction (HFrEF) and secondary mitral regurgitation (SMR), impaired right ventricular function (RVF) may negatively influence the prognosis. Percutaneous mitral valve repair (pMVR) can promote the recovery of RVF. We sought to characterize the response of the right ventricle to pMVR in HFrEF with SMR and to assess the association between improved RVF after pMVR and outcomes.Methods and results Overall, 221 patients with HFrEF and SMR >= 3+ successfully treated with pMVR in four tertiary care centres for heart failure were included. Improved RVF was defined as Delta right ventricular fractional area change (.RVFAC) >= 5% at early follow-up (median time 4 months). The primary endpoint was a composite of death/heart transplantation (D/HT). Mean age was 69 +/- 11 years, mean left ventricular ejection fraction was 31 +/- 8% and mean RVFAC was 34 +/- 9%. Delta RVFAC >= 5% occurred in 88 patients (40%) and was independent of the measures of left ventricular reverse remodelling. During a median follow-up of 29 months (interquartile range 12- 46), 81 patients (37%) reached the primary endpoint. After adjustment for other significant covariates,.RVFAC >= 5% was significantly associated with lower risk of D/HT (hazard ratio 0.52, 95% confidence interval 0.29-0.94, P = 0.030). In the secondary outcome analysis exploring the risk of heart failure hospitalizations, Delta VFAC >= 5% confirmed the prognostic association with the endpoint.Conclusions In patients with HFrEF and SMR, about 40% of patients improved RVF after pMVR. RVF improvement was associated with better long-term survival free from HT and lower risk of heart failure hospitalization.